This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.

Porcine endogenous retrovirus (PERV) genomes are present in all pig cells. In this retrospective study, we assessed PERV infectivity in 28 patients treated with an extracorporeal bioartificial liver (HepatAssist system) that includes a membrane device containing porcine hepatocytes. All patients tested negative for PERV using polymerase chain reaction analysis of peripheral blood mononuclear cells (PBMC) collected up to 5 years after treatment. In vitro results showed that the membrane decreased the risk of PERV transmission by a factor of 105, and porcine hepatocytes did not produce infectious PERV in co-cultures with human cell line 293. Our results do not support the presence of PERV infection in patients treated with this porcine hepatocyte-based bioartificial liver.

Based on perfusion of patient plasma through a circuit incorporating a hollow fibre membrane cartridge containing porcine hepatocytes, a bioartificial support system, or HepatAssist System, has been developed. Thirty-nine patients with acute liver failure (ALF) were treated in a Phase I multicentre clinical study. Thirty-two patients were bridged to orthotopic liver transplantation and six patients recovered without requiring a graft. Patient survival rate at one month was 90%. On the basis of these results, a multicentre Phase II/III, randomised, controlled, parallel group study of the HepatAssist System, compared to standard care in ALF patients has been initiated.

As cell-based therapies receive approval for clinical evaluation and use, the development of reliable methods to quantify cell number and control the dose of therapy delivered is becoming increasingly important. An example is the determination of the number and volume of primary porcine hepatocytes used in an extracorporeal treatment for patients with liver disease. Conventional cell counting using optical microscopy was compared against two alternate methods to quantify isolated porcine hepatocytes: (1) automated cell counting using a commercially available particle characterization instrument, and (2) quantitation by cell mass. Methods were compared based on accuracy, precision, specificity, linear range, and ruggedness. The automated method delivered substantially improved accuracy, precision, and ruggedness when compared to the conventional optical method. It also provided valuable information about the size distribution of cell preparations, which often contained clumps of cells, and showed that processing steps such as cryopreservation can alter the size characteristics of a cell population. The automated method was also faster, and was well suited to use in a commercial manufacturing process. The mass-based method was simple and inexpensive, but suffered from nonlinearity at low cell concentrations. Automated cell quantitation using a commercially available particle characterization instrument proved to be the preferred method for obtaining accurate and consistent porcine hepatocyte counts in a timely manner.

In this article, we examine the advanced clinical development of bioartificial organs and describe the challenges to implementing such systems into patient care. The case for bioartificial organs is evident: they are meant to reduce patient morbidity and mortality caused by the persistent shortage of organs available for allotransplantation. The widespread introduction and adoption of bioengineered organs, incorporating cells and tissues derived from either human or animal sources, would help address this shortage. Despite the decades of development, the variety of organs studied and bioengineered, and continuous progress in the field, only two bioengineered systems are currently commercially available: Apligraf® and Dermagraft® are both approved by the FDA to treat diabetic foot ulcers, and Apligraf® is approved to treat venous leg ulcers. Currently, no products based on xenotransplantation have been approved by the FDA. Risk factors include immunological barriers and the potential infectivity of porcine endogenous retrovirus (PERV), which is unique to xenotransplantation. Recent breakthroughs in gene editing may, however, mitigate risks related to PERV. Because of its primary role in interrupting progress in xenotransplantation, we present a risk assessment for PERV infection, and conclude that the formerly high risk has been reduced to a moderate level. Advances in gene editing, and more broadly in the field, may make it more likely than ever before that bioartificial organs will alleviate the suffering of patients with organ failure.